Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Been here around 3 years. My dad died in early 2017, suffered from diabetes, I heard about a diabetes stock that soared 15,000% and have been here ever since. I hope they can bring relief to the millions that suffer from this disease.
That’s a real possibility, wasn’t much on the ask below $.10
3 year high $.077
$.07 on deck
375k on the bid at .058
The news just keeps getting better and better!!
Lastone what do you know about the IDF?
I assume once this passes the trial, it’ll be made to ALRT’s users. Any updates on the two trials? Looking forward to an update soon, should be 2-3 months into both trials.
https://twitter.com/bionimeco/status/1292996179219816448?s=21
Would this be reference to the trial in Singapore?
If it’s so easy, why did it take LVGO a year to get acquired at nearly 8x the IPO price. It’s an emerging market, and takes a bit of patience and forward thinking. It would have been a lot cheaper to acquire them at say $50 a share.
That’s paying over 50k per patient.
Volume coming now, nearly at a million shares before lunch.
Future is looking very promising, especially with more news possibly on the way.
ALRT Launches Prediabetes Solution Completing Most Comprehensive Diabetes Management System Available Today
New Feature Will Expand the Scope of the ALRT Diabetes Solution to Help Prevent Diabetes
(July 27, 2020 -- RICHMOND, VA) ALR Technologies Inc. (OTCQB: ALRT) is launching the ALRT Prediabetes Solution. This is a new, prevention-based feature of the ALRT Diabetes Solution that is already well-positioned in the diabetes patient care marketplace. The new product was designed in direct response to discussions with government healthcare authorities for a scalable solution that could address the growing problem of prediabetes.
ALRT is making its new Prediabetes Solution available at no cost to health plans that are using the ALRT Diabetes Solution for their current beneficiaries who have diabetes. This will help payer groups manage the diabetes pandemic at its most treatable stage.
The newest features expand the scope of the ALRT Diabetes Solution, further cementing it as the most comprehensive diabetes management platform available on the market today. The Prediabetes Solution provides patients with educational videos and supplemental content formatted for mobile devices and a private online community to discuss disease management (e.g., support, weight loss, diet, etc.). Most importantly, the System tracks patients and reminds them to test their A1C according to payer protocols. This is the best way to ensure that patients get therapy as soon as they cross the threshold to overt diabetes. Effectively, the ALRT Prediabetes Solution gives patients access to all the products in the ALRT Diabetes Solution, less the blood glucose testing supplies and weekly reviews by the healthcare team.
“In our discussions with government healthcare authorities, we became acutely aware of their desire for turnkey technology that addresses both diabetes and prediabetes,” commented Sidney Chan, CEO of ALR Technologies. “Ultimately, most people with prediabetes will transition into diabetes, which is when costs start skyrocketing and quality of life diminishes. Our goal is to provide solutions that can delay, or even prevent, the onset of full-on disease, while getting patients and healthcare providers into the ALRT Diabetes Solution framework.”
The ALRT Prediabetes system will give patients the tools that they need to be proactive in monitoring their A1C. As with any disease, early detection is critical to controlling outcomes. As soon as a patient’s A1C exceeds the diagnostic threshold for diabetes, the healthcare provider can immediately prescribe the ALRT Diabetes Solution to closely monitor and guide the patient’s clinical progress.
“Prediabetes is a major concern for healthcare payers,” continued Mr. Chan. “We are now offering a turnkey prediabetes solution at no cost for both government and private health plans to aid in diabetes detection. This will help reduce treatment costs and hopefully result in slowing the accelerating diagnosis rate for diabetes, one of the most expensive chronic diseases in the world.”
“The ALRT blood glucose testing system uses one of the most accurate monitors available, yet it will cost less than most other testing platforms. For health plans that purchase the ALRT blood glucose testing system, the management system for Diabetes Solution and Prediabetes Solution will be available at no cost,” concluded Mr. Chan.
Someone got impatient
ALRT tweet based of this article
Now, imagine what you could do with a diabetes remote monitoring platform that enabled professional care teams (rather than the patients themselves) to manage thousands of people back to health simultaneously?
Any idea when we will hear about the results of the first trial?
The ALRT Diabetes Solution will be sold to patients on an annual subscription basis that includes the weekly reviews and all of their testing supplies at an all-in cost less than the retail price of testing supplies alone. Patients will receive comprehensive diabetes treatment that will be cost effective, timely, and easy to manage.
RICHMOND, Va., June 24, 2020 (GLOBE NEWSWIRE) -- ALR Technologies Inc. (OTCQB: ALRT) today announces that the ALRT Diabetes Solution will be available to diabetes patients through their private physicians across Singapore. ALRT Diabetes Solution is a diabetes management platform that offers a comprehensive approach to diabetes and includes Bionime’s Rightest GM700SB blood glucose meter and test strips.
The partnership with Bionime Corporation (“Bionime”) (TPE:4737) includes Bionime's marketing team calling on the private physician practices in Singapore and the larger private practice groups. Founded in 2003, Bionime provides best quality products to people with healthcare need and their care givers, so that they can easily manage their daily health.
The ALRT Diabetes Solution mitigates and contains diabetes complications by helping patients maintain blood glucose control and achieve A1C goals. According to the International Diabetes Federation, Singapore has the second-highest proportion of people with diabetes among developed nations.
The ALRT system will process uploaded blood glucose data from patients to provide doctors with clinical information and treatment plan suggestions based on best practice guidelines. Doctors will then provide their patients a weekly assessment of their diabetes. The ALRT Diabetes Solution will be sold to patients on an annual subscription basis that includes the weekly reviews and all of their testing supplies at an all-in cost less than the retail price of testing supplies alone. Patients will receive comprehensive diabetes treatment that will be cost effective, timely, and easy to manage.
The turnkey system is easily implemented. The doctors will provide an enrollment package that contains a high-quality Bionime blood glucose meter and all testing supplies. Test strip refills will be picked up by patients at their doctor’s office on a quarterly basis. Patients will be instructed to download the free ALRT App for mobile phones or tablets, compatible with Android and iOS devices and use Bluetooth to upload their blood glucose readings from their meters once per week. The ALRT system will process their data to render a Predictive A1C value that the doctors will use, along with the ALRT therapy advancement and Insulin Dose Adjustment algorithms. The goal is to ensure that there is timely titration of medication therapies.
The ALRT Diabetes Solution also gives providers a platform for remote diabetes care, helping to minimize patient exposure to potential infections in clinical settings. Remote diabetes patient management has gained much attention during the COVID-19 outbreak. Patients with diabetes who catch the virus are among the most vulnerable for clinical complications, so preventing their exposure is paramount.
The ALRT Diabetes Solution presents a clinically valuable yet affordable means of diabetes management for patients. Compensation for the weekly therapy reviews grants doctors a financial incentive to prescribe it. ALRT plans to take this innovative diabetes management system to other ASEAN countries, such as Malaysia, Indonesia, Brunei, Thailand, and the Philippines. Using this model, ALRT also will be able to reach diabetes patients through their doctors in East Asia (Japan, Korea, Taiwan and Hong Kong) and the Gulf Cooperation Council countries.
We have news. ALRT launches private practice across Singapore
Bold statement about possible future revenue. Patience is about to payoff!
I’m surprised that this hasn’t been bought out yet. I know it’s a “penny stock,” but the ROI for someone would be tremendous.
The latest 10q: 40,000,0000 options granted on June 12, 2019 were amended to extend the period of vesting from May 31, 2020 to December 31, 2020. None of these options have vested to date,
The expiration date of the options for the sales team, has been extended thru the end of the year.
Thanks lastone for the update, these are invaluable. I can’t imagine how relieved Mr. Chan is to have the first step in the process announced to the world. I also think that most companies wouldn’t want a “2nd” trial, but I assume the ALRT and Mr. Chan are confident in the outcome, and that the results can only help in getting their diabetes management system off the ground.
Lastone, thanks for your knowledge and dedication to this board. Without you I’d have sold along time ago.
What’s the end point target of the trail? Starting point is an A1C over 8%, how long will it take to get below 7%? 6%?
What if the participants are showing tremendous decline after 3 months, will the results be shared publicly or to other potential clients?
Can’t wait for the real run
Absolutely. If this trial partnership is successful, ALRT will be a home run.
It states that every quarter
A little more info on the LVGO contract, if interested
https://www.mobihealthnews.com/news/north-america/livongo-inks-deal-federal-employee-health-benefits-program-stock-jumps?utm_source=dlvr.it&utm_medium=twitter
I think there are over 2 million employees under FEHBP, so maybe there is room for another contract. I would assume there are more the 70,000 in that program with diabetes.
https://www.marketwatch.com/story/livongos-stock-soars-after-awarded-fehbp-contract-adding-up-to-60-million-in-revenue-2019-10-07?siteid=yhoof2&yptr=yahoo
LVGO is getting $25,000,000 in 2020 for 25,000 members. That’s $83 per month per member. Why isn’t ALRT getting this for $10 per??
And over 80 million with prediabetes
I know we all want some good news, but you have to respect the CEO for not putting out any fluff pieces. I think the lack of fluff really shows that something is in the pipeline, and hopefully coming soon. GLTA
Interested to find out the revenues of the new company, could send this flying
They have 164,000 patients. I hope someone realizes what a deal the ALRT system is and the deals are made quickly. This IPO should serve as a catalyst. A large company could snatch this up for next to nothing.